• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck Kgaa (OP:MKGAF)

161.80 +5.55 (+3.55%)
Delayed Quote Updated: 3:54 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 171
Open 160.97
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 156.25
Today's Range 158.51 - 168.24
52wk Range 116.68 - 175.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Invo Fertility Stock Is Plunging After White House Announcement ↗
October 17, 2025
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
October 17, 2025
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga

Performance

52-Week Range 7.8% below 52-week high
161.80
116.6852W Low 175.5652W High
1 Week 3.8% below 1-week high
152.731W Low 168.241W High

Merck Kgaa (MKGAF) traded between $116.68 and $175.56 over the past 52 weeks and last traded at $161.80, 7.8% below its 52-week high. Over the past week it ranged between $152.73 and $168.24.

Past 12 Months
+3.4%
+3.0%
+2.1%
+16.8%
+12.0%
+21.2%
1W +$5.35
1M +$4.75
3M +$3.29
6M +$23.29
YTD +$17.28
1Y +$28.28

MKGAF was +21.2% over the past year, +16.8% over six months, +12.0% year to date, +3.4% in the last week.

12 Months vs Market
MKGAF
+21.2%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months MKGAF returned +21.2% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.22× 3-mo avg
Today 171 3-mo avg 767.0
1W
307.0
1M
894.0
3M
767.0
6M
716.0
YTD
686.0
1Y
643.0

MKGAF most recently traded 171 shares against a 3-month average daily volume of 767.0.

More News

Read More
News headline image
EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗
October 17, 2025
Via Benzinga
Topics Government
News headline image
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗
September 26, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗
August 11, 2025
Via Benzinga
News headline image
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
July 22, 2025
From Crown Bioscience
Via JCN Newswire
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
February 16, 2025
Via Benzinga
News headline image
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗
February 11, 2025
Via Benzinga
Topics Intellectual Property
News headline image
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗
January 13, 2025
Via Benzinga
News headline image
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED ↗
August 17, 2024
Via Talk Markets
News headline image
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗
December 06, 2023
Via Benzinga
News headline image
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗
November 04, 2023
Via Talk Markets
News headline image
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗
September 26, 2023
Via Benzinga
News headline image
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗
August 03, 2023
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
July 26, 2023
Via Benzinga
News headline image
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗
June 20, 2023
Via Benzinga
News headline image
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗
May 17, 2023
Via Benzinga
News headline image
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗
April 18, 2023
Via Benzinga
News headline image
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗
April 12, 2023
Via Benzinga
News headline image
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗
March 27, 2023
Via Benzinga
News headline image
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗
March 23, 2023
Via Benzinga
News headline image
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗
January 03, 2023
Via Benzinga
News headline image
Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗
December 23, 2022
Via Benzinga
News headline image
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact ↗
September 30, 2021
Via Benzinga
News headline image
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study ↗
September 21, 2021
Via Benzinga

Frequently Asked Questions

Is Merck Kgaa publicly traded?
Yes, Merck Kgaa is publicly traded.
What exchange does Merck Kgaa trade on?
Merck Kgaa trades on the OTC Traded
What is the ticker symbol for Merck Kgaa?
The ticker symbol for Merck Kgaa is MKGAF on the OTC Traded
What is the current price of Merck Kgaa?
The current price of Merck Kgaa is 161.80
When was Merck Kgaa last traded?
The last trade of Merck Kgaa was at 10/16/26 03:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap